Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 127
Filter
1.
Clin Exp Allergy ; 43(12): 1342-50, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24261944

ABSTRACT

BACKGROUND: Eosinophilia is a marker of corticosteroid responsiveness and risk of exacerbation in asthma; although it has been linked to submucosal matrix deposition, its relationship with other features of airway remodelling is less clear. OBJECTIVE: The aim of this study was to investigate the relationship between airway eosinophilia and airway remodelling. METHODS: Bronchial biopsies from subjects (n = 20 in each group) with mild steroid-naïve asthma, with either low (0-0.45 mm(-2)) ) or high submucosal eosinophil (23.43-46.28 mm(-2) ) counts and healthy controls were assessed for in vivo epithelial damage (using epidermal growth factor receptor staining), mucin expression, airway smooth muscle (ASM) hypertrophy and inflammatory cells within ASM. RESULTS: The proportion of in vivo damaged epithelium was significantly greater (P = 0.02) in the high-eosinophil (27.37%) than the low-eosinophil (4.14%) group. Mucin expression and goblet cell numbers were similar in the two eosinophil groups; however, MUC-2 expression was increased (P = 0.002) in the high-eosinophil group compared with controls. The proportion of submucosa occupied by ASM was higher in both asthma groups (P = 0.021 and P = 0.046) compared with controls. In the ASM, eosinophil and T-lymphocyte numbers were higher (P < 0.05) in the high-eosinophil group than both the low-eosinophil group and the controls, whereas the numbers of mast cells were increased in the high-eosinophil group (P = 0.01) compared with controls. CONCLUSION: Submucosal eosinophilia is a marker (and possibly a cause) of epithelial damage and is related to infiltration of ASM with eosinophils and T lymphocytes, but is unrelated to mucus metaplasia or smooth muscle hypertrophy.


Subject(s)
Airway Remodeling , Asthma/immunology , Asthma/pathology , Eosinophilia/pathology , Adult , Asthma/metabolism , Case-Control Studies , Female , Goblet Cells/pathology , Humans , Hyperplasia , Male , Middle Aged , Mucins/metabolism , Muscle, Smooth/metabolism , Muscle, Smooth/pathology , Respiratory Mucosa/immunology , Respiratory Mucosa/metabolism , Respiratory Mucosa/pathology , Young Adult
2.
Front Allergy ; 4: 1236977, 2023.
Article in English | MEDLINE | ID: mdl-37577332

ABSTRACT

In March 2023, the European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual Summit in Brussels with expert panel members of EUFOREA, representatives of the EUFOREA patient advisory board, and the EUFOREA board and management teams. Its aim was to define the research, educational and advocacy initiatives to be developed by EUFOREA over the next 2 years until the 10th anniversary in 2025. EUFOREA is an international non-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic allergic and respiratory diseases via research, education, and advocacy. Based on its medical scientific core competency, EUFOREA offers an evidence-supported platform to introduce innovation and education in healthcare leading to optimal patient care, bridging the gap between latest scientific evidence and daily practice. Aligned with the mission of improving health care, the expert panels of asthma, allergic rhinitis (AR), chronic rhinosinusitis (CRS) & European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS), allergen immunotherapy (AIT) and paediatrics have proposed and elaborated a variety of activities that correspond to major unmet needs in the allergy and respiratory field. The current report provides a concise overview of the achievements, ambitions, and action plan of EUFOREA for the future, allowing all stakeholders in the allergy and respiratory field to be up-dated and inspired to join forces in Europe and beyond.

4.
Respir Med ; 150: 66-73, 2019 04.
Article in English | MEDLINE | ID: mdl-30961953

ABSTRACT

Gastro-oesophageal reflux disease (GORD) has long been associated with poor asthma control without an established cause-effect relationship. 610 asthmatics (421 severe/88 mild-moderate) and 101 healthy controls were assessed clinically and a subset of 154 severe asthmatics underwent proteomic analysis of induced sputum using untargeted mass spectrometry, LC-IMS-MSE. Univariate and multiple logistic regression analyses (MLR) were conducted to identify proteins associated with GORD in this cohort. When compared to mild/moderate asthmatics and healthy individuals, respectively, GORD was three- and ten-fold more prevalent in severe asthmatics and was associated with increased asthma symptoms and oral corticosteroid use, poorer quality of life, depression/anxiety, obesity and symptoms of sino-nasal disease. Comparison of sputum proteomes in severe asthmatics with and without active GORD showed five differentially abundant proteins with described roles in anti-microbial defences, systemic inflammation and epithelial integrity. Three of these were associated with active GORD by multiple linear regression analysis: Ig lambda variable 1-47 (p = 0·017) and plasma protease C1 inhibitor (p = 0·043), both in lower concentrations, and lipocalin-1 (p = 0·034) in higher concentrations in active GORD. This study provides evidence which suggests that reflux can cause subtle perturbation of proteins detectable in the airways lining fluid and that severe asthmatics with GORD may represent a distinct phenotype of asthma.


Subject(s)
Asthma/complications , Asthma/metabolism , Gastroesophageal Reflux/complications , Proteomics/methods , Sputum/metabolism , Adult , Asthma/epidemiology , Asthma/psychology , Endopeptidases/metabolism , European Union/organization & administration , Female , Gastroesophageal Reflux/diagnosis , Gastroesophageal Reflux/epidemiology , Humans , Immunoglobulin lambda-Chains/metabolism , Lipocalin 1/metabolism , Male , Middle Aged , Prevalence , Prospective Studies , Protease Inhibitors/metabolism , Quality of Life , Severity of Illness Index
5.
Eur Respir J ; 31(4): 714-24, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18094008

ABSTRACT

The bronchial epithelium is an important physical barrier that regulates physiological processes including leukocyte trafficking. The aim of the present study was to elucidate the mechanisms whereby the bronchial epithelium, stimulated by epidermal growth factor (EGF) as part of a response to acute or chronic injury, could activate and chemoattract human neutrophils. Subconfluent human bronchial epithelial (16HBE) cells were stimulated with EGF to mimic the in vivo events after injury. The effect of the resulting EGF-conditioned media (CM) was compared with that of basal-CM with respect to neutrophil activation and chemotaxis. Such findings were then confirmed using primary bronchial epithelial cells (PBECs) from healthy volunteers. EGF-CM from 16HBE cells caused increased expression of CD11b/CD66b and CD62L loss on neutrophils when compared with basal-CM. EGF-CM contained significant neutrophil chemotactic activity involving granulocyte-macrophage colony-stimulating factor and interleukin-8 that was potentiated by leukotriene B(4). This was dependent on neutrophil phosphatidylinositol-3-kinase activation and Akt phosphorylation, with partial regulation by phospholipase D, but not mammalian target of rapamycin. Consistent with these observations, EGF-CM derived from PBECs displayed increased chemotactic activity. The present results suggest that the enhanced chemotactic activity of the epidermal growth factor-conditioned epithelium can enhance neutrophil-mediated immunity during acute injury, while during continued injury and repair, as in chronic asthma, this could contribute to persistent neutrophilic inflammation.


Subject(s)
Bronchi/immunology , Chemotaxis, Leukocyte/immunology , Epidermal Growth Factor/immunology , Inflammation/immunology , Neutrophils/immunology , Bronchi/cytology , Cell Line , Culture Media, Conditioned , Epidermal Growth Factor/physiology , Epithelial Cells/immunology , Humans , Respiratory Distress Syndrome/immunology , Signal Transduction
6.
J Clin Invest ; 99(5): 879-87, 1997 Mar 01.
Article in English | MEDLINE | ID: mdl-9062345

ABSTRACT

CGP 51901 is a non-anaphylactogenic mouse/human chimeric anti-human IgE antibody that binds to free IgE and surface IgE of IgE-expressing B cells but not to IgE bound to high affinity IgE receptors (Fc epsilonR1) on mast cells and basophils or low affinity IgE receptors (Fc epsilonR2) on other cells. A phase 1 double-blind, placebo-controlled, single dose study with doses of 3, 10, 30, and 100 mg of CGP 51901 was conducted in 33 pollen-sensitive subjects who had raised levels of serum IgE and received either intravenous CGP 51901 or placebo. The administration of CGP 51901 was well tolerated and resulted in a decrease of serum free IgE levels in a dose-dependent manner, with suppression after 100 mg of CGP 51901 reaching > 96%. Time of recovery to 50% of baseline IgE correlated with the dose of administered antibody and ranged from a mean of 1.3 d for the 3 mg to 39 d for the 100 mg dose. Total IgE, comprised of free and complexed IgE, increased as stored and newly synthesized IgE bound to CGP 51901. Complexed IgE was eliminated at a rate comparable with the terminal half-life of free CGP 51901 (11-13 d at all doses). Only one subject showed a weak antibody response against CGP 51901. We conclude that the use of anti-human IgE antibody is safe and effective in reducing serum IgE levels in atopic individuals and provides a potential therapeutic approach to the treatment of atopic diseases.


Subject(s)
Antibodies, Anti-Idiotypic/therapeutic use , Chimera/immunology , Immunoglobulin E/analysis , Immunoglobulin E/immunology , Rhinitis, Allergic, Seasonal/drug therapy , Adolescent , Adult , Animals , Antibodies, Anti-Idiotypic/administration & dosage , Antibodies, Anti-Idiotypic/adverse effects , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Basophils/metabolism , Chromatography, High Pressure Liquid , Dose-Response Relationship, Drug , Dose-Response Relationship, Immunologic , Double-Blind Method , Histamine Release , Humans , Immunoglobulin E/blood , Male , Mice , Middle Aged , Pollen/immunology , Radioallergosorbent Test , Skin Tests
8.
J Immunol Methods ; 189(1): 107-15, 1996 Jan 16.
Article in English | MEDLINE | ID: mdl-8576572

ABSTRACT

Highly enriched CD4+ and CD8+ human T cells were obtained from peripheral blood using a relatively simple and inexpensive method consisting of four steps: separation of mononuclear cells on Lymphoprep, removal of adherent monocytes by incubation in plastic petri dishes, removal of B cells, NK cells and further depletion of nonadherent monocytes by panning with anti-CD19, -CD16, -CD14, -CD11b and -CD33 mAb, and separation of CD4+ and CD8+ T lymphocytes by magnetic cell sorting (MACS). Cell culture for up to 48 h showed preservation of function by both positively and negatively selected cells as determined by production of IL-8. Although the cell separation procedure had no effect on interleukin-2 receptor (IL-2R, CD25) expression, it induced production of IL-4 by both T cell subsets selected positively, implying cell activation by ligation of CD4 and CD8 molecules. Irrespective of the mode of separation, CD8+ T cells produced more IL-4, a cytokine which is associated with a Th2-type cytokine profile of CD4+ T cells. We conclude that our method for separating T cells into their CD4+ and CD8+ subsets results in high cell purities with preservation of function, as determined by cytokine generation. If enriched cells are to be used for functional studies we recommend isolation by negative selection which has less effect on cell function. The relevance of the finding that CD8+ T cells can be an important source of IL-4 remains to be elucidated.


Subject(s)
CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Immunomagnetic Separation , Interleukin-4/biosynthesis , Interleukin-8/biosynthesis , Cell Adhesion/immunology , Cell Survival/immunology , Concanavalin A/pharmacology , Flow Cytometry , Humans , Immunomagnetic Separation/methods , Monocytes/immunology , Phytohemagglutinins/pharmacology
9.
Chest ; 120(6): 1815-21, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11742907

ABSTRACT

BACKGROUND: Sputum induction by hypertonic saline solution inhalation is widely used to study airways secretions in patients with asthma. However, hypertonic saline solution is a potent indirect bronchoconstrictor. STUDY OBJECTIVES: We studied the validity of isotonic saline solution (0.9%) inhalation as a means to induce sputum by comparing it to hypertonic saline solution (4.5%) inhalation. PATIENTS: Sixteen patients with moderate-to-severe asthma reporting a clinical history of mucus hypersecretion. METHODS: Subjects underwent sputum induction twice at 1-week intervals. Saline solution (hypertonic or isotonic) was inhaled for three periods of 5 min. The parameters assessed in sputum samples were cell counts, sodium, eosinophil cationic protein (ECP), and albumin concentrations, osmolality, and pro-matrix metalloproteinase (MMP)-9 activity by zymography. RESULTS: The maximal fall in peak expiratory flow during sputum induction was greater after inhalation of hypertonic saline solution than after inhalation of isotonic saline solution (p < 0.01). Each subject produced analyzable sputum on both visits. There were no statistically significant differences in total and differential sputum cell counts, and the reproducibility coefficients were high for eosinophils and neutrophils when comparing the two methods. Likewise, sputum levels of ECP and albumin as well as sputum pro-MMP-9 activity were not different between the two methods, and were highly reproducible as shown by high intraclass coefficients (Ri) of correlation (0.72, 0.74, and 0.77 for ECP, albumin, and pro-MMP-9, respectively). Sputum sodium concentrations and osmolality were higher after inhalation of hypertonic saline solution (p < 0.05). CONCLUSION: In patients with moderate-to-severe asthma reporting a clinical history of mucus hypersecretion, inducing sputum by isotonic or hypertonic saline solution inhalation leads to comparable results in eosinophil and neutrophil cell counts and fluid phase mediators/proteins.


Subject(s)
Asthma/diagnosis , Ribonucleases , Saline Solution, Hypertonic , Sodium Chloride , Sputum , Administration, Inhalation , Adult , Aged , Asthma/immunology , Blood Proteins/metabolism , Double-Blind Method , Eosinophil Granule Proteins , Eosinophils/immunology , Female , Humans , Leukocyte Count , Male , Matrix Metalloproteinase 9/metabolism , Middle Aged , Neutrophils/immunology , Osmolar Concentration , Peak Expiratory Flow Rate , Predictive Value of Tests , Sputum/cytology , Sputum/immunology
10.
J Appl Physiol (1985) ; 89(4): 1283-92, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11007560

ABSTRACT

Pulmonary surfactant in bronchoalveolar lavage fluid (BALF) and induced sputum from adults with stable asthma (n = 36) and healthy controls (n = 12) was analyzed for phospholipid and protein compositions and function. Asthmatic subjects were graded as mild, moderate, or severe. Phospholipid compositions of BALF and sputum from control subjects were similar and characteristic of surfactant. For asthmatic subjects, the proportion of dipalmitoyl phosphatidylcholine (16:0/16:0PC), the major phospholipid in surfactant, decreased in sputum (P < 0.05) but not in BALF. In BALF, mole percent 16:0/16:0PC correlated with surfactant function measured in a capillary surfactometer, and sputum mole percent 16:0/16:0PC correlated with lung function (forced expiratory volume in 1 s). Neither surfactant protein A nor total protein concentration in either BALF or sputum was altered in asthma. These results suggest altered phospholipid composition and function of airway (sputum) but not alveolar (BALF) surfactant in stable asthma. Such underlying surfactant dysfunction may predispose asthmatic subjects to further surfactant inhibition by proteins or aeroallergens in acute asthma episodes and contribute to airway closure in asthma. Consequently, administration of an appropriate therapeutic surfactant could provide clinical benefit in asthma.


Subject(s)
Asthma/physiopathology , Bronchoalveolar Lavage Fluid/chemistry , Forced Expiratory Volume/physiology , Phospholipids/analysis , Pulmonary Surfactants/analysis , Sputum/chemistry , Adolescent , Adult , Bronchoalveolar Lavage Fluid/cytology , Eosinophils , Female , Humans , Male , Middle Aged , Proteolipids/analysis , Pulmonary Surfactant-Associated Proteins , Spectrometry, Mass, Secondary Ion , Sputum/cytology
11.
Respir Med ; 96(2): 67-80, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11862964

ABSTRACT

The small airways constitute one of the least understood areas of the lungs. They play a role in many lung diseases, and small airway pathology results in significant morbidity New approaches to their evaluation may provide insights into this major area of lung disease. Asthma is well recognized as a disease of both large and small airways. Physiological and pathological evidence, from techniques such as post-mortem tissue histological analysis, induced sputum and transbronchial biopsies, has reinforced the concept of the involvement of the entire bronchial tree n the inflammatory process in asthma, In addition to describing the airway pathology in asthma, th s review focuses on the pathogenesis and role of small airway obstruction n other diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), sarcoidosis and obliterative bronchiolitis (OB). COPD is characterized by the presence of airflow obstruction resulting from lesions in the small airways. In addition, features compatible with small airways disease are common in IPF, sarcoidosis and OB. Recent advances in pulmonary imaging, such as high-resolution computed tomography (HRCT) and magnetic resonance imaging (MRI) with hyperpolarized 3He, have allowed non-invasive reproducible measurements of structure-function relationships to be made for the small airways. These techniques have great potential for diagnosing changes in small airway function and for assessing responses to treatment. New insights into the contribution of small airways to a range of lung diseases may lead to the development of therapies targeted at this part of the bronchial anatomy.


Subject(s)
Bronchi/pathology , Lung Diseases/pathology , Bronchiolitis Obliterans/drug therapy , Bronchiolitis Obliterans/pathology , Drug Delivery Systems , Glucocorticoids/therapeutic use , Humans , Lung Diseases/drug therapy , Magnetic Resonance Imaging , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/pathology , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/pathology , Respiratory Function Tests , Sarcoidosis/drug therapy , Sarcoidosis/pathology , Tomography, X-Ray Computed
12.
Monaldi Arch Chest Dis ; 51(1): 30-4, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8901318

ABSTRACT

Theophylline has traditionally been considered for its effect on airway calibre in the treatment of bronchial asthma. However, in this respect theophylline is less potent than the current highly selective beta-agonists. In view of the accumulated evidence of potent effects of this nonspecific phosphodiesterase inhibitor on several inflammatory cell types, there is increasing belief that the anti-inflammatory potential of theophylline may be central to its beneficial effects in the treatment of airways inflammatory diseases such as asthma. This is based on its ability to attenuate the late phase asthmatic response and to prevent an influx of eosinophils and T-cells both in the setting of experimental allergen challenge and in clinical disease.


Subject(s)
Asthma , Bronchodilator Agents/therapeutic use , Theophylline/therapeutic use , Asthma/drug therapy , Asthma/immunology , Bronchodilator Agents/administration & dosage , Bronchodilator Agents/pharmacology , Cytokines/drug effects , Dose-Response Relationship, Drug , Eosinophils/drug effects , Humans , T-Lymphocytes/drug effects , Theophylline/administration & dosage , Theophylline/pharmacology , Treatment Outcome
13.
Rev Mal Respir ; 20(2 Pt 1): 215-23, 2003 Apr.
Article in French | MEDLINE | ID: mdl-12844019

ABSTRACT

INTRODUCTION: The technique of induced expectoration generates sputum by the inhalation of hypertonic saline. On account of its non-invasive character, its simplicity, its relative harmlessness, its cost effectiveness and its reproducibility this technique, that appeared in the early 1990's, has rapidly established itself as the technique of choice in the investigation of bronchial inflammation in asthma. STATE OF THE ART: We present the results of our studies that have contributed to the validation of the technique at the methodological level and to the exploitation of the cellular contents as much as the fluid phase of the expectorations in characterising bronchial inflammation in asthmatics. Our results confirm an infiltration of the airways of asthmatics with eosinophils that appears to be proportional to the severity of the illness. We evaluate the effect of inhaled steroids and of theophylline on sputum eosinophilia and bronchial reactivity and discuss the role of eosinophils on bronchial hyperreactivity. Finally we discuss the use of induced expectoration in clinical practice in asthma. PERSPECTIVES: The analysis of induced sputum could well become a valuable tool in the clinical evaluation and monitoring of asthma in the same way as symptoms and abnormalities of lung function. CONCLUSIONS: Induced expectoration has certainly contributed to the understanding of the cellular and molecular mechanisms of asthma as well as the role of bronchial inflammation in the clinical manifestations of the disease.


Subject(s)
Asthma/diagnosis , Saline Solution, Hypertonic , Specimen Handling/methods , Sputum/cytology , Asthma/classification , Asthma/drug therapy , Asthma/immunology , Biomarkers/analysis , Cost-Benefit Analysis , Eosinophils/immunology , Humans , Inflammation , Leukocyte Count , Reproducibility of Results , Severity of Illness Index , Specimen Handling/economics , Specimen Handling/standards , Sputum/chemistry , Sputum/immunology
14.
Biotech Histochem ; 86(5): 340-4, 2011 Oct.
Article in English | MEDLINE | ID: mdl-20662603

ABSTRACT

Toxic injury can induce squamous metaplasia of respiratory epithelium, which normally is pseudostratified. Terminally differentiated squamous epithelial cells have a flattened, elongated appearance. During differentiation, they have an intermediate phenotype that is difficult to identify and distinguish from tangentially cut columnar cells in tissue sections from endobronchial biopsies, whose small size makes orientation difficult. The aim of our study was to develop a panel of antibodies that could be employed to distinguish normal epithelium from metaplastic epithelium and would be suitable for use on endobronchial biopsies. Nasal polyp tissue and tonsil tissue, which have pseudostratified and squamous epithelia, respectively, were collected from surgical cases and embedded in glycol methacrylate resin. Cut sections were stained immunohistochemically with a panel of antibodies to cytokeratins (CK), whose expression varies with epithelial type and stage of differentiation, and involucrin, a marker of terminal squamous differentiation. Squamous epithelium stained positively for CK5/6, CK13 and involucrin. In the pseudostratified epithelium, basal cells exhibited weak staining for CK13 and strong staining for CK5/6, and columnar cells exhibited strong immunoreactivity for CK7, CK8 and CK18. Application of this panel to endobronchial biopsies from smokers enabled areas of squamous metaplasia to be distinguished from tangentially sectioned epithelium.


Subject(s)
Antibodies/metabolism , Bronchi/metabolism , Bronchi/pathology , Keratins/metabolism , Smoking/adverse effects , Biopsy , Epithelial Cells/metabolism , Epithelial Cells/pathology , Epithelium/metabolism , Humans , Immunohistochemistry , Metaplasia/etiology , Metaplasia/metabolism
19.
Thorax ; 61(5): 448-54, 2006 May.
Article in English | MEDLINE | ID: mdl-16648353

ABSTRACT

Airway inflammation is central to the pathogenesis of both airway remodelling and parenchymal destruction in chronic obstructive pulmonary disease (COPD). Neutrophils, macrophages, and CD8+ T lymphocytes have been implicated in a number of studies, but a detailed profile of disease-phenotype specific inflammation has yet to emerge. The heterogeneity of the disease has hindered data interpretation while extrapolation of the results of relatively non-invasive studies to the actual pathology found in the distal lung is difficult. Moreover, prominent studies have had frequently conflicting results. Further investigations are needed to marry the different clinical phenotypes of COPD to their respective inflammatory profiles in the airways and thus improve our understanding of the pathogenesis of the disease as a whole.


Subject(s)
Bronchitis/pathology , Pulmonary Disease, Chronic Obstructive/pathology , Eosinophils/pathology , Humans , Lymphocytes/pathology , Macrophages/pathology , Mast Cells/pathology , Neutrophils/pathology
20.
Eur Respir J ; 28(6): 1163-9, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16971404

ABSTRACT

Neutrophilic airway inflammation is a prominent feature of chronic obstructive pulmonary disease (COPD) and correlates with disease severity. The mechanisms that determine the extent of neutrophilia could involve increased influx or prolonged survival of neutrophils. The aim of the study was to assess whether neutrophil pro-survival mechanisms are increased in the airways of subjects with COPD owing to the presence of anti-apoptotic factors in the bronchial lining fluid. Induced sputum samples were collected from 20 subjects with stable COPD, 14 healthy smokers and 14 healthy controls. Quantification of apoptotic neutrophils was based on typical morphological cell changes. Anti-apoptotic, pro-survival activity in the sputum was studied by culturing peripheral blood neutrophils with the fluid phase of induced sputum. Apoptosis was assessed both by morphology and flow cytometry using Annexin V/7-aminoactinomycin D staining. COPD patients and healthy smokers had significantly higher percentages of sputum neutrophils than healthy controls. However, there were no significant differences between the three subject groups in either the proportion of apoptotic neutrophils in sputum or the in vitro anti-apoptotic activity detected in the sputum fluid phase. In conclusion, prolonged survival of neutrophils in sputum is not a feature of chronic obstructive pulmonary disease and cannot explain the increased numbers of airway neutrophils in this disease.


Subject(s)
Apoptosis/physiology , Neutrophils/pathology , Pulmonary Disease, Chronic Obstructive/physiopathology , Respiratory System/pathology , Adult , Aged , Annexin A5/metabolism , Case-Control Studies , Cells, Cultured , Female , Flow Cytometry , Follow-Up Studies , Forced Expiratory Volume/physiology , Humans , Male , Middle Aged , Neutrophil Activation/physiology , Pulmonary Disease, Chronic Obstructive/complications , Pulmonary Disease, Chronic Obstructive/drug therapy , Respiratory System/metabolism , Smoking/physiopathology , Sputum/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL